Ronac Mamtani, MD, MSCE

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Slater RL, Lai Y, Zhong Y, Li H, Meng Y, Homet Moreno B, Godwin JL, Frenkl T, Sonpavde GP, Mamtani R.: The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. J Med Econ May 2020.

Bange EM, Doucette A, Gabriel PE, Porterfield F, Harrigan JJ, Wang R, Wojcieszynski AP, Boursi B, Mooney BI, Reiss KA, Mamtani R.: Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JCO Oncol Pract March 2020.

Takvorian SU, Oganisian A, Mamtani R, Mitra N, Shulman LN, Bekelman JE, Werner RM.: Association of Medicaid Expansion Under the Affordable Care Act With Insurance Status, Cancer Stage, and Timely Treatment Among Patients With Breast, Colon, and Lung Cancer. JAMA Netw Open Feb 2020.

Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncol Jan 2020.

Ben Boursi, Jared S Huber, Kevin Haynes, Ronac Mamtani, Yu-Xiao Yang : Digoxin use is associated with pancreatic cancer risk but does not affect survival. Cancer Causes Control 2020.

Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R.: Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. Clin Genitourin Cancer 2020.

Margalit O, Shacham-Shmueli E, Yang YX, Lawerence YR, Levy I, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Mamtani R, Boursi B.: Prognostic Implications of Tumor Differentiation in Clinical T1N0 Gastric Adenocarcinoma. Oncologist 2020.

Ravi B Parikh , Kyle W Robinson , Sumedha Chhatre , Elina Medvedeva , John P Cashy , Shika Veera , Joshua M Bauml , Tito Fojo , Amol S Navathe , S Bruce Malkowicz , Ronac Mamtani , Ravishankar Jayadevappa : Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018. JAMA Netw Open 2020.

Parikh RB, Feld EK, Galsky MD, Adamson BJ, Cohen AB, Baxi SS, Boursi SB, Christodouleas JP, Vaughn DJ, Meropol NJ, Mamtani R.: First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. Future Oncol. Dec 16 2019 Notes: [Epub ahead of print]

Vajravelu RK, Copelovitch L, Osterman MT, Scott FI, Mamtani R, Lewis JD, Denburg MR.: Risk for Chronic Kidney Disease in Patients with Inflammatory Bowel Diseases Increases with Age but is not Associated with 5-aminosalicylate Use. Clin Gastroenterol Hepatol pii: S1542-3565(19): 31245-5, Nov 1 2019.

back to top
Last updated: 11/19/2020
The Trustees of the University of Pennsylvania